Nora Volkow Leads the World's Biggest Funder of Addiction Research, And

Total Page:16

File Type:pdf, Size:1020Kb

Nora Volkow Leads the World's Biggest Funder of Addiction Research, And Feature THE SCIENTIST BATTLING THE ADDICTION CRISIS Nora Volkow leads the world’s biggest funder of addiction research, and now she’s facing her greatest test in the opioid crisis. By Emiliano Rodríguez Mega n a cold Friday night in February 1995, for another few days and was sent home with comeback of cocaine and methamphetamine, addiction researcher Nora Volkow more. But she decided not to take it. She was and a two-decade-old opioid epidemic that has and her husband got into their car afraid — she knew many of her patients could devastated many parts of the country: opioid after a long day at Brookhaven not stop once they started. She would get overdoses have killed nearly half a million peo- National Laboratory in Upton, New through the pain without the help of drugs. ple in the United States (see ‘Tackling the opioid York. Ice had covered the trees and That night, a discomfort she had never felt epidemic’). In response, her agency has started the roads, making them sparkle. But before overran her body. She felt restless, projects to monitor drug use and has ploughed as the couple drove down a slope, agitated, desperate. Volkow took a painkiller money into medications that can reduce the Othe tyres lost their grip. The vehicle spun out and, like an apparition, the feeling faded away. cravings and pleasurable effects of drugs. of control. Volkow curled up to shield herself as “It was then that I realized how fast depend- Critics have long argued that Volkow’s an oncoming car crashed into her door. ence develops,” she says. “It also made me emphasis on the brain minimizes the roles Metal bit into her flesh. The pain was realize that I’m very afraid of opiates.” that social and economic forces have in mak- unrelenting. Finally, the fire service arrived Twenty-five years later, Volkow’s name has ing people prone to addiction. In the past year, to break her free and an ambulance rushed her become widely known in the addiction field and Volkow has begun to acknowledge that factors to the nearest emergency department, where beyond. As a neuroscientist who has directed such as homelessness, unemployment and a doctor gave her Demerol, a powerful and the US National Institute on Drug Abuse (NIDA) isolation can make people more vulnerable highly addictive opioid painkiller also known in Rockville, Maryland, since 2003, she has to drugs and less likely to recover. But some as pethidine, which is similar to morphine. championed the idea of addiction as a disease researchers contend that the agency’s funding Volkow had spent countless hours talking to of the brain rather than a moral failing. Under decisions have been slow to reflect this shift people with addiction and had read hundreds her direction, NIDA has prioritized research on in mindset. They say that NIDA’s focus on the of papers on the mechanisms of drug abuse. the biological basis of addiction, and fought brain is disproportionate, and they worry Neither prepared her for what happened next. against the mistreatment of drug abusers in about its outsized power over policies tack- “It was extraordinary, those impressive both the medical and criminal-justice systems. ling drug use and addiction. “NIDA’s influence sensations,” she says. A moment of ecstasy, Her quest has taken on a new urgency as is significant; people follow that lead,” says one she describes as comparable only to the United States finds itself contending with Ingrid Walker, a cultural-studies researcher long-lasting sexual pleasure, eclipsed all shifts in the legal status of cannabis, a grow- at the University of Washington in Tacoma. other feelings. She stayed on the medication ing market for electronic cigarettes, a sudden Nonetheless, Volkow’s obsession with 178 | Nature | Vol 580 | 9 April 2020 ©2020 Spri nger Nature Li mited. All ri ghts reserved. ©2020 Spri nger Nature Li mited. All ri ghts reserved. says Brodie. “Her enthusiasm was boundless.” Volkow soon became involved in every project, from looking for brain-tumour biomarkers1 to detecting differences in brain activity between people with and without schizophrenia2. Her reputation as a rebellious yet brilliant scientist began to take shape. “Nora was certain that she was always right, and sometimes she was,” says Brodie. “Perhaps, even, most of the time.” Scanning for insights By the mid-1980s, Volkow had completed a psychiatry residency at NYU and moved to the University of Texas Health Science Center in Houston to work in its imaging facility. She intended to study schizophrenia, but the cocaine craze was bringing with it a surge of addicted people. In PET scan after PET scan, Volkow spotted anomalies in these individuals’ brains. “You’d see holes, gaps where blood flow should be,” she says. She suggested that cocaine chokes blood vessels to the extent that they don’t allow proper circulation3 — similar to small strokes. Her findings contradicted the belief, common at the time, that cocaine was a relatively safe substance — although the 1986 deaths of two celebrated US sportsmen (basketball player Len Bias and American football player Don Rogers) changed that perception. In 1987, Volkow moved to Brookhaven National Laboratory, where for the next 16 years she continued to probe the effects of drugs on the brain. She used radioisotopes to label cocaine, tracking how rapidly it triggers the neurotransmitter dopamine in the brain Nora Volkow at her childhood home in Mexico City. and how quickly it dissipates, and arguing that the speed of its effect could explain why the understanding the biological effects of do with science, the answer was ‘yes’,” she says. drug is so powerfully addictive. NATURE excessive drug use — fuelled in part by her own She once asked him if she could bring home a While at Brookhaven, Volkow kept question- family’s past — has not only shattered dogmas corpse and dissect it. He approved; Volkow’s ing long-held assumptions in neuroscience. in neuroscience; it has also helped to mitigate mother and sisters threatened to leave the The general agreement was that addictive the stigma faced by those living with addiction. house. But she did end up with some bones to substances impaired the brain’s reward “Her mission in life was to harvest the power examine. “When something interests me,” she centres, tempting people to keep trying the ALEJANDRA RAJAL FOR FOR RAJAL ALEJANDRA of science to change lives of millions of peo- says, “I won’t quit until I understand it.” substances to feel good. But that didn’t explain ple,” says Bertha Madras, a psychobiologist That same curiosity and stubbornness why so many patients had told her that they felt at Harvard Medical School who is based at would guide most of her career. After graduat- compelled to take the drugs, even when they McLean Hospital in Belmont, Massachusetts. ing top of her class, she was accepted to study had long lost that pleasure. It was as if they had “And she has done that.” psychology at the Massachusetts Institute of lost the power to decide. This more-complex Technology in Cambridge. But a 1980 article in reaction seemed to implicate more than just Revolutionary heritage Scientific American disrupted her plans. the brain areas that process reward. Volkow grew up in Mexico City, one of four The piece described how a new technol- A series of key discoveries came in the 1990s. daughters of Soviet and Spanish immigrants. ogy, positron emission tomography (PET), Volkow noticed that the prefrontal cortex, the Their mother, an haute-couture dressmaker was allowing neuroimagers to look into brain region that regulates decision-making from Madrid, sought refuge in Mexico to escape living brains and watch their activity patterns. and self-control, was underactive in men who Francisco Franco’s dictatorship. Their father, Volkow was instantly hooked. were addicted to cocaine — an anomaly that a chemist, was also a refugee. He had come to Soon after reading the article, she secured a might sometimes precede addiction, making Mexico City as a 13-year-old in 1939 to live with research job in the lab of psychiatrist Jonathan a person more vulnerable to it. Dysfunction his only surviving relative — his grandfather, the Brodie at what was then New York University in decision-making regions, she suggested, exiled Soviet revolutionary leader Leon Trotsky. (NYU) Medical Center in New York City, which was why drug-addicted people felt they had As a teenager, Volkow was captivated by had a vibrant programme using the technol- lost control. Furthermore, she and her team the human brain and studied medicine at the ogy for neuroimaging. Brodie was starting to found, repeated cocaine use desensitized the National Autonomous University of Mexico in do PET scans with the aim of studying various brain by killing off dopamine receptors, which Mexico City. Her father encouraged her with- brain disorders in people. diminished the reward people felt from the out limits. “Whatever I asked my dad that had to “Clearly, she was a star from the beginning,” drug even as it increased their dependence on Nature | Vol 580 | 9 April 2020 | 179 ©2020 Spri nger Nature Li mited. All ri ghts reserved. ©2020 Spri nger Nature Li mited. All ri ghts reserved. Feature it4. Volkow and her colleagues later replicated until it changed its policy in 2018, the FDA — absorbing the history of Volkow’s family. these results in people who had misused had approved such treatments only if they Volkow has come back to Mexico City to visit alcohol, heroin or methamphetamine. could show that they fostered abstinence7. relatives, as she does almost every year. She The blobby PET images were diagnostic And Volkow alleges (although some critics stares at the little metal door in the headstone enough for Volkow to identify which belonged disagree) that reframing addiction as a patho- that contains her great-grandfather’s urn and to addicted people and which didn’t.
Recommended publications
  • April 16, 2021 Addiction in the News
    UC CAR Weekly Newsletter 4.16.2021 Welcome to the weekly newsletter from the Center for Addiction Research! Each newsletter includes highlights from addiction in the news topics, active funding opportunities offered by NIDA/NIAAA, and information about any new publications from CAR members. Please email Jen Rowe ([email protected]) to change your communication preferences. Thank you. Thank you for your interest in the Center for Addiction Research - our mission is to accelerate scientific progress in the prevention and treatment of substance use disorders and their consequences by fostering research collaborations across: 1) UC departments, colleges, and centers including Cincinnati Children’s Hospital Medical Center; 2) Local, regional, and state community and governmental partners; and 3) Other academic institutions and industry." April 16, 2021 Addiction in the News UC/ Regional News Center for Addiction Research to hold Summer Speaker Series The College of Medicine’s Center for Addiction Research will hold a Summer Speaker Series to discuss the innovative work and ongoing projects with the community related to prevention, intervention and treatment. The series is hosted by the Urban Health Pathway of Next Lives Here. Monthly presentations begin in May and run through August. Featured CAR presenters will be Drs. Burlew, Blackard, Lyons and Merhar. (pdf attached) >> Register for any of the presentations The 'Other Epidemic' Of Opioids Rages On Last week, the Ohio Department of Mental Health and Addiction Services announced $13 million in new grants awarded to community organizations trying to reduce opioid overdoses in the state. That's right, another epidemic is still raging while we tap the "refresh" buttons on our browsers hoping for our COVID-19 vaccination appointments.
    [Show full text]
  • April 9, 2021 Addiction in the News
    UC CAR Weekly Newsletter 4.9.2021 Welcome to the weekly newsletter from the Center for Addiction Research! Each newsletter includes highlights from addiction in the news topics, active funding opportunities offered by NIDA/NIAAA, and information about any new publications from CAR members. Please email Jen Rowe ([email protected]) to change your communication preferences. Thank you. Thank you for your interest in the Center for Addiction Research - our mission is to accelerate scientific progress in the prevention and treatment of substance use disorders and their consequences by fostering research collaborations across: 1) UC departments, colleges, and centers including Cincinnati Children’s Hospital Medical Center; 2) Local, regional, and state community and governmental partners; and 3) Other academic institutions and industry." April 9, 2021 Addiction in the News UC/ Regional News Opinion: Our society often punishes individuals struggling with addiction The recent settlement announced between the state of Ohio and consulting business McKinsey & Co. for the firm's role in creating and fueling the opioid epidemic is a perfect example of how we unfairly punish Ohioans dealing with substance-use disorder while allowing the engineers of this crisis to escape with just a slap on the wrist. More than 200,000 lives have been lost to the opioid… The Opioid Crisis Was America’s Epidemic Before COVID. Research Suggests that Overdoses Hurt Student Achievement Long before the emergence of COVID-19, the United States was struggling to contain a years-long opioid crisis that took tens of thousands of lives every year. Now, with Oxycontin manufacturer Purdue Pharma still negotiating billion-dollar penalties for its role in the two-decade drug epidemic, experts have begun taking the measure of its impact on student learning.
    [Show full text]
  • Clinical Trials Network.” This Presentation the NIDA CCC (Clinical Coordinating Center) and DSC Was Co-Authored by Dr
    CTN Bulletin Clinical Trials May 22, 2013 Network Volume 13 - 08 Trial Progress – Over 15,000! Greater New York Node News The Greater New York Node held its semiannual Node Trial enrollment numbers reflect study and Stakeholders Meeting May 3rd information as of May 21, 2013. at NYU School of Medicine. Participants included representatives from all of their Open Studies Community Treatment Providers, • CTN 0048 – CURB (Cocaine Use Reduction with New York University, Columbia University, Cornell Buprenorphine). Enrolled 302 (N=300). Enrollment University and The Rockefeller University, as well as completed – Completed follow-up, data lock next. leaders from the New York City Department of Health • CTN 0049 – Project HOPE (Hospital Visit as and Mental Hygiene, the New York City Health and Opportunity for Prevention and Engagement for Hospitals Corporation, the New York State Office of HIV-Infected Drug Users). Enrolled 475 (N=800). Alcoholism and Substance Abuse Services and the • CTN 0050 – Long Term Follow-up to the CTN Northeast and Caribbean Basin ATTC. Drs. Betty Tai 0027 (START) Study. Enrolled 813 (N=1,267). and Udi Ghitza joined from NIDA CCTN. Foci of the • CTN 0052 – BRAC (Buspirone for Relapse- meeting included: (1) integrating and coordinating Prevention in Adults with Cocaine Dependence). addictions screening and interventions across mainstream Enrolled 62 (N=60). Enrollment completed – in and specialty settings; (2) the use of technology to follow up phase. facilitate this; (3) scaling up and implementation research; and (4) an update on how addictions research Total Enrolled All Studies: 15,905 and practice were sustained in the wake of Hurricane Sandy.
    [Show full text]
  • Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations for 2017
    DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, EDUCATION, AND RELATED AGENCIES APPROPRIATIONS FOR 2017 HEARINGS BEFORE A SUBCOMMITTEE OF THE COMMITTEE ON APPROPRIATIONS HOUSE OF REPRESENTATIVES ONE HUNDRED FOURTEENTH CONGRESS SECOND SESSION SUBCOMMITTEE ON THE DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, EDUCATION, AND RELATED AGENCIES TOM COLE, Oklahoma, Chairman MICHAEL K. SIMPSON, Idaho ROSA L. DELAURO, Connecticut STEVE WOMACK, Arkansas LUCILLE ROYBAL-ALLARD, California CHARLES J. FLEISCHMANN, Tennessee BARBARA LEE, California ANDY HARRIS, Maryland CHAKA FATTAH, Pennsylvania MARTHA ROBY, Alabama CHARLES W. DENT, Pennsylvania E. SCOTT RIGELL, Virginia NOTE: Under Committee Rules, Mr. Rogers, as Chairman of the Full Committee, and Mrs. Lowey, as Ranking Minority Member of the Full Committee, are authorized to sit as Members of all Subcommittees. SUSAN ROSS, JOHN BARTRUM, JENNIFER CAMA, JUSTIN GIBBONS, KATHRYN SALMON, and LORI BIAS, Subcommittee Staff PART 6 Page National Institutes of Health ................................................ 1 Department of Education ...................................................... 167 Centers for Disease Control and Prevention ................... 215 ( Printed for the use of the Committee on Appropriations U.S. GOVERNMENT PUBLISHING OFFICE 21–343 WASHINGTON: 2016 COMMITTEE ON APPROPRIATIONS HAROLD ROGERS, Kentucky, Chairman RODNEY P. FRELINGHUYSEN, New Jersey NITA M. LOWEY, New York ROBERT B. ADERHOLT, Alabama MARCY KAPTUR, Ohio KAY GRANGER, Texas PETER J. VISCLOSKY, Indiana MICHAEL K. SIMPSON, Idaho JOSE´ E. SERRANO, New York JOHN ABNEY CULBERSON, Texas ROSA L. DELAURO, Connecticut ANDER CRENSHAW, Florida DAVID E. PRICE, North Carolina JOHN R. CARTER, Texas LUCILLE ROYBAL-ALLARD, California KEN CALVERT, California SAM FARR, California TOM COLE, Oklahoma CHAKA FATTAH, Pennsylvania MARIO DIAZ-BALART, Florida SANFORD D. BISHOP, JR., Georgia CHARLES W.
    [Show full text]
  • Director's Report
    Director's Report to the NATIONAL ADVISORY COUNCIL ON DRUG ABUSE September 2012 Nora D. Volkow, M.D. Director National Institute on Drug Abuse TABLE OF CONTENTS RESEARCH HIGHLIGHTS .................................................................................. 3 CONGRESSIONAL AFFAIRS ........................................................................... 11 NIH/HHS POLICY UPDATES ............................................................................ 13 PROGRAM ACTIVITIES/FOAS ........................................................................ 13 NIDA PUBLICATIONS ........................................................................................ 18 PRESS RELEASES ............................................................................................ 18 MEETINGS/CONFERENCES ........................................................................... 19 COMMUNITY AND PRESS EVENTS .............................................................. 20 STAFF HONORS AND AWARDS .................................................................... 21 STAFF CHANGES .............................................................................................. 22 IN MEMORIAM .................................................................................................... 24 * These sections contain select information. More comprehensive information will be posted in the September 2012 Staff Report to the Director. 1 2 RESEARCH HIGHLIGHTS Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression
    [Show full text]
  • CIHR Assessment of the Canadian Guideline for Opioids for Chronic Non-Cancer Pain
    Discoveries for life CIHR Assessment of the Canadian Guideline for Opioids for Chronic Non-Cancer Pain At the Canadian Institutes of Health Research (CIHR), we know that research has the power to change lives. As Canada's health research investment agency, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system. Canadian Institutes of Health Research 160 Elgin Street, 9th Floor Address Locator 4809A Ottawa, Ontario K1A 0W9 www.cihr-irsc.gc.ca Also available on the Web in PDF and HTML formats © Her Majesty the Queen in Right of Canada (2017) Cat. No. MR4-61/2017E-PDF ISBN 978-0-660-09692-6 2 1. Context Canada is experiencing a dramatic rise in opioid-related deaths. In 2016 alone, almost 2,500 opioid-related deaths occurred across Canadai. Likewise, the number of opioid prescriptions filled in Canada each year is increasingii. In Ontario alone, the number of opioid prescriptions filled increased by five per cent over three years (2013-14 to 2015- 16) while the number of people who filled at least one of these prescriptions remained approximately the sameiii. Inappropriate opioid prescribing practices is one factor contributing to this growing crisis as cases arise of patients becoming addicted while under the care of a physician. In 2010, recognizing the need to improve safe opioid prescribing practices, a national group of physicians and researchers developed the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. This guideline provided recommendations to medical professionals on prescribing opioids safely and effectively.
    [Show full text]
  • Biography of Dr. Nora Volkow
    Biography of Dr. Nora Volkow Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. Dr. Volkow’s work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs. Her studies have documented changes in the dopamine system affecting, among others, the functions of frontal brain regions involved with motivation, drive, and pleasure in addiction. She has also made important contributions to the neurobiology of obesity, ADHD, and aging. Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Robins award for best medical student of her generation. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA. Dr. Volkow spent most of her professional career at the Department of Energy’s Brookhaven National Laboratory (BNL) in Upton, New York, where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a Professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.
    [Show full text]
  • Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(G)(5)
    Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(g)(5) 1. Your Name: Nora D Volkow 2. Your Title: IC Director 3. The Entity(ies) You are Representing: NIDA/NIH/DHHS 4. Are you testifying on behalf of the Federal, or a State or local Yes No government entity? X 5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. N/A 6. Please attach your curriculum vitae to your completed disclosure form. Signature:___ ________________Date:_________________10/24/2017 Nora Volkow M.D. Director, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) Nora D. Volkow, M.D., became Director of NIDA in May 2003. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. Dr. Volkow’s work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs. Her studies have documented changes in the dopamine system affecting, among others, the functions of frontal brain regions involved with motivation, drive, and pleasure in addiction. She has also made important contributions to the neurobiology of obesity, ADHD, and aging.
    [Show full text]
  • News Advisory***
    National Institute on Drug Abuse http://www.drugabuse.gov/ _______________________________________________________________________ FOR IMMEDIATE RELEASE Contact: NIDA Press Office Friday, May 3, 2013 301-443-6245 [email protected] ***NEWS ADVISORY*** NIDA’s Dr. Nora Volkow joins President Clinton on Clinton Foundation’s prescription drug abuse panel Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, will join President Bill Clinton, New York dignitaries, and college students from New York University for a panel discussion on prescription drug abuse. The panel will address prescription drug abuse, particularly among 18 – 26 year olds, and how the Clinton Foundation’s Clinton Health Matters Initiative can work with others to contribute to solutions in New York and nationwide. WHAT: Prescription Drug Abuse: A Forum with President Clinton, Commissioner Ray Kelly, NYU President John Sexton, and Dr. Nora Volkow Hosted by the Clinton Foundation’s Clinton Health Matters Initiative WHEN: Monday, May 6, 2013 10:30 a.m. EST (Press must check in by 9:45 a.m. EST) WHERE: New York University School of Law Vanderbilt Hall, Greenberg Lounge 40 Washington Square South New York, N.Y. 10012 Media interested in attending must RSVP by May 5 to [email protected]. WHO: Featured Speakers President Bill Clinton Founder, Clinton Foundation 42nd President of the United States Raymond W. Kelly Police Commissioner, City of New York John Sexton, Ph.D., J.D. President, New York University Nora D. Volkow, M.D. Director, National Institute on Drug Abuse For more information on prescription drug misuse, visit: www.drugabuse.gov/drugs- abuse/prescription-drugs.
    [Show full text]
  • U.S. Department of Health and Human Services National Institutes of Health
    U.S. Department of Health and Human Services National Institutes of Health Minutes of the Fourth Joint Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, National Advisory Council on Drug Abuse, and National Cancer Advisory Board February 11, 2016 Rockville, Maryland Members of the National Advisory Council on Alcohol Abuse and Alcoholism (NIAAA), National Advisory Council on Drug Abuse (NIDA), and the National Cancer Advisory Board of the National Cancer Institute (NCI) convened for their fourth joint meeting on February 11, 2016, in Rockville, Maryland. Chaired by Dr. George Koob, Director of NIAAA, and Dr. Nora Volkow, Director of NIDA, this open session convened at 9:03 a.m. National Advisory Council on Alcohol Abuse and Alcoholism Members Present: Carmen E. Albizu-Garcia, M.D. Carol A. Casey, M.D. Carlo C. DiClemente, Ph.D. Thomas Donaldson Karen Drexler, M.D. (Ex Officio) James H. Eberwine, Ph.D. Joseph Thomas Flies-Away, J.D., M.P.A. Paul J. Gruenewald, Ph.D. Paul Kenney, Ph.D. Joe L. Martinez, Ph.D. Sarah N. Mattson Weller, Ph.D. Robert O. Messing, M.D. Patricia E. Molina, Ph.D. Adolf Pfefferbaum, M.D. Arun J. Sanyal, M.D. Rajita Sinha, Ph.D. Frank A. Sloan, Ph.D. Constance M. Weisner, D.R.P.H. National Advisory Council on Drug Abuse Members Present: Anne C. Andorn, M.D. Judith D. Auerbach, Ph.D. Laura J. Bierut, M.D. Julie A, Blendy, Ph.D. Regina M. Carelli, Ph.D. John Carnevale, Ph.D. Arthur T. Dean Marie Gallo Dyak (ad hoc) 1 Jay N.
    [Show full text]
  • Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
    Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender Health Policy, Research, Professional Education, and Clinical Care September 27-28, 2018 FDA White Oak Campus, Bldg. 31, Great Room Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender A INTRODUCTION Sex differences may influence susceptibility to substance use disorders, which could have implications for optimal prevention and treatment. Gender influences also impact public health by influencing prescription rates, care, and treatment-seeking behaviors. To identify and treat at-risk women, researchers, educators, and clinicians must be able to recognize and consider sex and gender differences in substance use, misuse, and recovery. The U.S. Food and Drug Administration’s Office of Women’s Health, in collaboration with the Center for Drug Evaluation and Research and Center for Tobacco Products, presents this 2-day meeting, Scientific Conference — Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender, to address this important issue. This conference will include presentations by experts in the fields of opioid and tobacco research, professional education, and clinical care on the biological (sex) and sociological (gender) influences on use, misuse, and recovery. LEARNING OBJECTIVES In relation to the sex and gender differences associated with opioid and nicotine use, dependence, and recovery, meeting participants will: Appreciate the sex and gender interactions in outcomes across the lifespan; understand the unique role of Health & Human Services (HHS) and other federal stakeholders; recognize research gaps and emerging therapeutic areas for drugs, devices, and behavioral approaches; recognize the necessity of a comprehensive, integrative approach to the treatment of addiction.
    [Show full text]
  • EDUCATION Is Needed Most
    April 5–8 LIVE IN NASHVILLE When things feel so uncertain, EDUCATION is needed most. We look forward to welcoming our attendees back to the most influential annual conference addressing the addiction crisis. LEARN MORE about the Rx Summit Commitment to Safe Connections > Nancy Hale, MA President and CEO, Operation UNITE Educational Advisor The Rx Summit is where solutions are formulated and CHANGE BEGINS For 4 days, the wide range of stakeholders impacted by prescription drug misuse and illicit drug use come together to address this public health emergency. Attend what you can live, and watch the rest on demand with our Maximum Access Package. Rx Summit is committed to delivering critical education in a safe and responsible manner. Our team is working diligently to implement safety measures and protocols to ensure we can meet next April with complete peace of mind. Stay tuned in the coming months for more information regarding Rx Summit’s Commitment to Safe Connections. 2 RX DRUG ABUSE & HEROIN SUMMIT The opioid crisis is growing Prescription more complex as more people opioid misuse The Opioid concurrently use stimulants and the long-term impacts costs the U.S. of the coronavirus pandemic Epidemic emerge. Everything we do matters. We can turn around by the these dire numbers. Join us in discussing what’s $78.5 Numbers making a difference. billion a year 10.3 million 808,000 people misused people used heroin in 2018 prescription opioids 81,000 in 2018 people used heroin for the first time 128people in the U.S. 15,349 2 million die from
    [Show full text]